CRE to FDA/TPSAC: Allow Public Comment on Peer Review Plans for Menthol as Statutorily Required
The FDA has released material its October meeting.
The FDA material references initiation and cessation studies. The overwhelming number of these studies were reviewed in detail by the CRE DQA petition.
Should not the CRE DQA petition be reviewed by TPSAC as part of its review of the studies identified by FDA?
Is the TPSAC going to submit a report which complies with the DQA or is going to ignore the statute and send a report which the FDA can not use?
What is the role of the non-voting tobacco representatives in the preparation of the report?
